Previous close | 0.4000 |
Open | 0.8000 |
Bid | 0.2000 |
Ask | 0.8000 |
Strike | 17.50 |
Expiry date | 2024-05-17 |
Day's range | 0.8000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | 27 |
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.